Tofacitinib Postmarketing Data Shed Light on JAK Inhibitor Risks Tofacitinib Postmarketing Data Shed Light on JAK Inhibitor Risks
Analyses of the phase 3b/4 ORAL Surveillance trial results found independent factors for risk for major adverse cardiovascular events, cancer, and venous thromboembolic events.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Rheumatology News Source Type: news
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Heart | Oral Cancer | Rheumatology